Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11802269-B2
Publication Date
2023-10-31
Expiration Date
Abstract
The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
Core Innovation
The disclosure describes a fusion protein comprising the amino acid sequence of SEQ ID NO: 40, including nucleic acid embodiments and embodiments associated with vectors and host cells. It further describes genome editing compositions that use CRISPR-based elements and type IIS endonucleases, including Clo051, and inactive and fusion-configured genome editing components, including dCas9-Clo051 fusion constructs.
The document relates these concepts to modified cells, including modified T cells, modified stem memory T cells (TSCM), and modified central memory T cells (TCM). It describes methods of producing modified cells by introducing the fusion protein defined by SEQ ID NO: 40 into a cell, and further narrows the modified cell to T cells and specific T cell subtypes.
The disclosure also describes transposon systems and genomic integration concepts, including piggyBac, Super piggyBac, Sleeping Beauty, Helraiser/Helitron, and Tol2, as well as CAR-related cell engineering approaches for producing modified T cells. It further includes mRNA or nanoparticle vectors and viral vector systems as approaches for producing engineered or modified cells.
Claims Coverage
The claim coverage centers on a single inventive feature defined by the amino acid sequence of SEQ ID NO: 40, with dependent limitations to producing modified cells, including T cells, modified TSCM or TCM, and an allogeneic embodiment.
Fusion protein defined by SEQ ID NO: 40
A fusion protein comprising the amino acid sequence of SEQ ID NO: 40.
Producing a modified cell by introducing the fusion protein
A method of producing a modified cell by introducing into the cell the fusion protein.
Producing a modified T cell
The method wherein the modified cell is a T cell.
Producing modified stem memory T cells or modified central memory T cells
The method wherein the modified T cell is a modified stem memory T cell (TSCM) or a modified central memory T cell (TCM).
Allogeneic modified T cell embodiment
The method wherein the modified T cell is an allogenic cell.
The claim coverage is anchored on the fusion protein defined by SEQ ID NO: 40 and dependent method limitations for producing modified cells, including T cells, modified TSCM or TCM, and an allogeneic embodiment.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?